Education
About Us
Working with TipRanks
Follow Us
Fusen Pharmaceutical Co., Ltd. (HK:1652)
:1652
1652 Stock Chart & Stats
HK$0.80
-HK$0.03(-4.41%)
At close: 4:00 PM EST
HK$0.80
-HK$0.03(-4.41%)
Day’s Range― - ―
52-Week RangeHK$0.24 - HK$1.75
Previous CloseN/A
Volume70.00K
Average Volume (3M)1.23M
Market Cap
HK$683.76M
Enterprise ValueHK$909.47M
Total Cash (Recent Filing)HK$75.99M
Total Debt (Recent Filing)HK$364.67M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Apr 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding739,301,000
10 Day Avg. Volume642,000
30 Day Avg. Volume1,233,253
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.50
Price to Sales (P/S)1.71
P/FCF Ratio9.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsMultiple durable revenue channels — prescription drugs, OTC products, collaborations and licensing — reduce single-product dependence and smooth cash flow volatility. Licensing and partnerships provide non-linear revenue upside and recurring royalties that support long-term business resilience.
R&D And Product Pipeline FocusAn explicit strategic emphasis on innovation and pipeline expansion across oncology, cardiology and infectious disease creates a sustainable avenue for future growth. Successful clinical or licensing milestones would improve margins and competitive positioning over multiple years.
Stable Equity RatioA stable equity ratio indicates a degree of capital structure resilience even as leverage exists. That stability can help preserve access to financing and support investment into R&D or manufacturing, providing a firmer foundation for medium-term operational plans.
Bears Say
Sharp Revenue ContractionA roughly 43% revenue decline is a structurally negative signal: it erodes scale advantages, reduces the ability to fund R&D and commercialization, and pressures pricing power. Sustained revenue contraction impairs long-term competitiveness and recovery runway.
Weak Cash GenerationZero/negative operating and free cash flow indicate the company cannot reliably self-fund operations or growth. Over months to years this raises liquidity risk, forces external financing, and can constrain drug development, product launches, and commercial expansion.
Elevated Leverage And Falling EquityA debt-to-equity around 1.0 coupled with declining shareholders' equity raises refinancing and solvency concerns. Higher leverage limits strategic flexibility, increases interest burden, and magnifies downside in an industry where long R&D cycles require stable funding.
Fusen Pharmaceutical Co., Ltd. News
1652 FAQ
What was Fusen Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Fusen Pharmaceutical Co., Ltd. lowest stock price was HK$0.23 and its highest was HK$1.75 in the past 12 months.
What is Fusen Pharmaceutical Co., Ltd.’s market cap?
Fusen Pharmaceutical Co., Ltd.’s market cap is HK$683.76M.
When is Fusen Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Fusen Pharmaceutical Co., Ltd.’s upcoming earnings report date is Apr 07, 2026 which is in 43 days.
How were Fusen Pharmaceutical Co., Ltd.’s earnings last quarter?
Fusen Pharmaceutical Co., Ltd. released its earnings results on Aug 29, 2025. The company reported -HK$0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.034.
Is Fusen Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Fusen Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Fusen Pharmaceutical Co., Ltd. pay dividends?
Fusen Pharmaceutical Co., Ltd. pays a Notavailable dividend of HK$0.004 which represents an annual dividend yield of N/A. See more information on Fusen Pharmaceutical Co., Ltd. dividends here
What is Fusen Pharmaceutical Co., Ltd.’s EPS estimate?
Fusen Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusen Pharmaceutical Co., Ltd. have?
Fusen Pharmaceutical Co., Ltd. has 739,301,000 shares outstanding.
What happened to Fusen Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Fusen Pharmaceutical Co., Ltd. reported an EPS of -HK$0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Fusen Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1652
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fusen Pharmaceutical Co., Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.18%
12-Months-Change
Fundamentals
Return on Equity
-40.38%
Trailing 12-Months
Asset Growth
-6.03%
Trailing 12-Months
Company Description
Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.
Technical Analysis
Tianda Pharmaceuticals Ltd.
―
China NT Pharma Group Co., Ltd.
―
PuraPharm Corp. Ltd.
―
Zhongzhi Pharmaceutical Holdings Limited
―
Huakang Biomedical Holdings Company Limited
―